BORON NEUTRON-CAPTURE THERAPY OF MALIGNANT-MELANOMA USING B-10-PARABORONOPHENYLALANINE WITH SPECIAL REFERENCE TO EVALUATION OF RADIATION-DOSE AND DAMAGE TO THE NORMAL SKIN

被引:81
作者
FUKUDA, H
HIRATSUKA, J
HONDA, C
KOBAYASHI, T
YOSHINO, K
KARASHIMA, H
TAKAHASHI, J
ABE, Y
KANDA, K
ICHIHASHI, M
MISHIMA, Y
机构
[1] KAWASAKI MED SCH, DEPT RADIOL, KURASHIKI, OKAYAMA 70101, JAPAN
[2] KOBE UNIV, SCH MED,DEPT DERMATOL, KOBE 650, JAPAN
[3] KYOTO UNIV, INST RES REACTOR, KUMATORI, OSAKA 59004, JAPAN
[4] SHINSHU UNIV, FAC PHYS,DEPT CHEM, MATSUMOTO, NAGANO 370, JAPAN
[5] HYGO MED CTR, AKASHI, HYOGO, JAPAN
[6] KOBE KAISEI HOSP, DEPT DERMATOL, KOBE 657, JAPAN
关键词
D O I
10.2307/3578693
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A treatment regimen for boron neutron capture therapy of malignant melanomas is described using B-10-paraboronophenyl-alanine as the tumor-targeting compound. As a therapeutic dose, we adopted the maximum tolerable dose for the skin regardless of tumor B-10 concentration. In practice, the maximum neutron fluence should be decided prior to starting irradiation. For this purpose, the kinetics of the concentration of B-10 in the blood and skin and the skin-to-blood ratios were analyzed in the six patients who received 170 mg/kg of the compound intravenously, and skin concentrations during irradiation were predicted using a standard skin factor curve. This yields a skin concentration at time T based on the blood concentration at time 0. We calculated the maximum tolerable fluence yielding but not exceeding 18 RBE-Gy by assuming that the RBE of N-14(n,p)C-14 and B-10(n,alpha)Li-7 reaction for skin damage is 2.5. Actual skin reactions in three of five patients treated with therapy were, as predicted, within tolerable limits, and we were able to obtain complete tumor regression in four cases. The results indicate that application of our logicla approach will be useful for subsequent cases and further development of this therapy.
引用
收藏
页码:435 / 442
页数:8
相关论文
共 23 条
[1]   IMPLICATIONS OF THE QUADRATIC CELL-SURVIVAL CURVE AND HUMAN-SKIN RADIATION TOLERANCE DOSES ON FRACTIONATION AND SUPER-FRACTIONATION DOSE SELECTION [J].
DOUGLAS, BG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (07) :1135-1142
[2]   DEVELOPMENT AND DOSIMETRY OF AN EPITHERMAL NEUTRON BEAM FOR POSSIBLE USE IN NEUTRON CAPTURE THERAPY .2. ABSORBED DOSE MEASUREMENTS IN A PHANTOM MAN [J].
FAIRCHILD, RG ;
GOODMAN, LJ .
PHYSICS IN MEDICINE AND BIOLOGY, 1966, 11 (01) :15-+
[3]  
FUKUDA H, 1992, PROGRESS IN NEUTRON CAPTURE THERAPY FOR CANCER, P511
[4]   ESTIMATION OF ABSORBED DOSE IN THE COVERING SKIN OF HUMAN-MELANOMA TREATED BY NEUTRON-CAPTURE THERAPY [J].
FUKUDA, H ;
KOBAYASHI, T ;
HIRATSUKA, J ;
KARASHIMA, H ;
HONDA, C ;
YAMAMURA, K ;
ICHIHASHI, M ;
KANDA, K ;
MISHIMA, Y .
PIGMENT CELL RESEARCH, 1989, 2 (04) :365-369
[5]  
Hatanaka H., 1991, GLIOMA, P233
[6]   THE RELATIVE BIOLOGICAL EFFECTIVENESS OF B-10-NEUTRON CAPTURE THERAPY FOR EARLY SKIN REACTION IN THE HAMSTER [J].
HIRATSUKA, J ;
FUKUDA, H ;
KOBAYASHI, T ;
KARASHIMA, H ;
YOSHINO, K ;
IMAJO, Y ;
MISHIMA, Y .
RADIATION RESEARCH, 1991, 128 (02) :186-191
[8]  
ISHIWATA K, 1992, NUCL MED BIOL, V19, P311
[9]   B-11 MRI AND MRS OF INTACT ANIMALS INFUSED WITH A BORON NEUTRON-CAPTURE AGENT [J].
KABALKA, GW ;
DAVIS, M ;
BENDEL, P .
MAGNETIC RESONANCE IN MEDICINE, 1988, 8 (02) :231-237
[10]  
KANDA K, 1975, BIOMEDICAL DOSIMETRY, P205